Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial

BACKGROUND: Prostate cancer is the most commonly diagnosed malignancy in the UK. Castrate resistant prostate cancer (CRPC) can be difficult to manage with response to next generation hormonal treatment variable. AR-V7 is a protein biomarker that can be used to predict response to treatment and poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Gravestock, Paul, Clark, Emma, Morton, Miranda, Sharma, Shirya, Fisher, Holly, Walker, Jenn, Wood, Ruth, Hancock, Helen, Waugh, Nichola, Cooper, Aislinn, Maier, Rebecca, Marshall, John, Chandler, Robert, Bahl, Amit, Crabb, Simon, Jain, Suneil, Pedley, Ian, Jones, Rob, Staffurth, John, Heer, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614403/
https://www.ncbi.nlm.nih.gov/pubmed/37035713
http://dx.doi.org/10.3310/nihropenres.13284.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614403/
https://www.ncbi.nlm.nih.gov/pubmed/37035713
http://dx.doi.org/10.3310/nihropenres.13284.2

Ejemplares similares